Acute on chronic liver failure – Diagnostics – Overview of Information and Clinical Research

Acute on chronic liver failure is a serious medical syndrome that requires careful evaluation and specialized testing to identify and monitor the multiple organ systems that can be affected.

Introduction: Who Should Undergo Diagnostics

Diagnostic testing for acute on chronic liver failure—a term that describes sudden and severe worsening of liver function in people who already have long-standing liver disease—becomes essential when certain warning signs appear. People with chronic liver conditions such as cirrhosis should seek medical evaluation immediately if they experience sudden confusion, yellowing of the skin or eyes, increasing belly swelling, or dark-colored urine. These symptoms may signal that the liver is no longer able to perform its vital functions and that other organs are beginning to fail.^[1]

Anyone with a history of chronic liver disease who develops new or worsening symptoms should undergo diagnostic evaluation without delay. This includes individuals who have been living with conditions caused by alcohol use, hepatitis B or C infection, fatty liver disease, or other causes of long-term liver damage. The importance of timely testing cannot be overstated, as acute on chronic liver failure can progress rapidly and lead to life-threatening complications within days or weeks.^[2]

Diagnostic testing is particularly urgent when a person with known cirrhosis experiences what doctors call an acute decompensation—a sudden worsening that might show up as a new infection, bleeding from the digestive tract, buildup of fluid in the abdomen, or changes in mental state. These events can trigger the cascade of organ failures that define acute on chronic liver failure. Early recognition through appropriate testing allows healthcare teams to intervene quickly and potentially prevent further deterioration.^[3]

⚠️ Important

If you or someone you know with liver disease suddenly develops yellowing of the eyes or skin, confusion or personality changes, or severe upper belly pain, seek emergency medical attention immediately. Acute on chronic liver failure can be life-threatening and requires urgent evaluation in a hospital setting where specialized testing and treatment are available.

The decision to pursue diagnostic evaluation should not wait until symptoms become severe. People with chronic liver disease benefit from regular monitoring even when they feel relatively well, as this allows doctors to detect early signs of worsening function. However, when new symptoms appear suddenly—particularly if they involve the brain, kidneys, lungs, heart, or blood clotting system—immediate and comprehensive diagnostic testing becomes a medical priority.^[4]

Diagnostic Methods for Identifying the Condition

The diagnostic process for acute on chronic liver failure involves multiple types of testing that work together to paint a complete picture of how the liver and other organs are functioning. Blood tests form the foundation of this evaluation, providing critical information about liver enzymes, bilirubin levels, blood clotting ability, and kidney function. When doctors suspect acute on chronic liver failure, they typically order comprehensive blood panels that measure substances the liver normally processes or produces.^[1]

One of the most important blood tests measures bilirubin, a yellow pigment that builds up when the liver cannot process it properly. High bilirubin levels cause the yellowing of skin and eyes known as jaundice. Doctors also check the international normalized ratio or INR, which shows how well blood clots—when the liver fails, the blood’s ability to clot becomes impaired, leading to dangerous bleeding risks. Additional blood tests examine levels of albumin (a protein the liver makes), creatinine (which indicates kidney function), and sodium, all of which help determine the severity of organ dysfunction.^[15]

Laboratory testing extends beyond basic chemistry panels to include complete blood counts, which reveal problems with platelets and red blood cells, and tests for infection markers. Since bacterial infections often trigger acute on chronic liver failure or develop as a complication, doctors may order cultures of blood, urine, or fluid from the abdomen to identify any infectious organisms. The presence of infection significantly influences treatment decisions and prognosis.^[3]

Imaging studies play a valuable role in understanding what is happening inside the body. Ultrasound examinations of the abdomen allow doctors to visualize the liver, check for fluid accumulation, and assess blood flow through the liver’s vessels. This non-invasive test uses sound waves to create pictures of internal organs and can detect problems like blood clots or tumors that might be contributing to liver failure. In some cases, more advanced imaging such as computed tomography (CT) scans or magnetic resonance imaging (MRI) may be necessary to get a clearer view of the liver and surrounding structures.^[13]

Assessment of organ function goes beyond the liver itself to examine how well other body systems are working. Doctors evaluate kidney function through blood tests and urine output measurements, as kidney failure commonly occurs alongside liver failure. Brain function is assessed through physical examination and mental status testing to detect hepatic encephalopathy—confusion and altered consciousness caused by toxins that the failing liver cannot remove from the blood. The cardiovascular system is monitored through blood pressure measurements and tests that check heart function.^[4]

Respiratory function requires careful evaluation as well, since lung complications can develop in acute on chronic liver failure. Doctors measure oxygen levels in the blood using a simple finger clip device called a pulse oximeter, and they may need to perform arterial blood gas tests that analyze oxygen and carbon dioxide levels more precisely. These tests help determine whether mechanical ventilation or other respiratory support might be necessary.^[8]

In certain situations, a liver biopsy—removal of a small piece of liver tissue for microscopic examination—may provide additional diagnostic information. However, this procedure carries risks in people with acute on chronic liver failure because their blood may not clot properly. When a biopsy is deemed necessary, doctors often use a special technique called transjugular liver biopsy, which approaches the liver through a vein in the neck rather than through the skin and abdomen. This method reduces the risk of dangerous bleeding.^[13]

The diagnostic workup must also identify any precipitating events—the triggers that caused the sudden worsening of chronic liver disease. The most common triggers include bacterial infections, bleeding from veins in the digestive tract, excessive alcohol use, viral hepatitis flares, and certain medications that are toxic to the liver. Identifying these triggers is crucial because treating them directly can help stabilize the patient’s condition. Doctors take detailed medical histories and order specific tests based on what they suspect might have initiated the acute deterioration.^[3]

Scoring systems help doctors organize all this diagnostic information into a meaningful assessment of disease severity. The CLIF-C ACLF score, developed by European researchers, evaluates six organ systems—liver, kidney, brain, blood clotting, circulation, and lungs—and assigns grades from 1 to 3 based on how many organs are failing. This scoring system helps predict short-term survival and guides decisions about intensive care and liver transplantation. Different medical societies around the world use slightly different criteria, but all aim to systematically evaluate the extent of organ failure.^[8]

⚠️ Important

Diagnostic testing for acute on chronic liver failure differs from testing for acute liver failure alone or simple worsening of cirrhosis. The condition requires evaluation of multiple organ systems, not just the liver, because the defining feature is the development of failures in organs beyond the liver itself. This comprehensive approach ensures that all affected body systems receive appropriate attention and treatment.

The distinction between acute on chronic liver failure and other liver conditions requires careful clinical judgment. Unlike acute liver failure, which occurs suddenly in people with previously healthy livers, acute on chronic liver failure develops in individuals with long-standing liver disease. It also differs from acute decompensated cirrhosis, which represents worsening of cirrhosis complications without the multiple organ failures that characterize acute on chronic liver failure. Proper diagnosis depends on recognizing this pattern of sudden deterioration with extrahepatic (outside the liver) organ dysfunction in someone with chronic liver disease.^[3]

Diagnostics for Clinical Trial Qualification

When patients with acute on chronic liver failure are considered for participation in clinical trials testing new treatments, they undergo additional diagnostic evaluations beyond standard clinical care. These research studies require precise documentation of disease severity and organ function to ensure that participants meet specific eligibility criteria and that trial results can be properly interpreted. The diagnostic requirements for clinical trial enrollment are typically more detailed and standardized than those used in routine practice.^[4]

Clinical trials for acute on chronic liver failure commonly use validated scoring systems as entry criteria. The CLIF-C ACLF score, the NACSELD (North American Consortium for the Study of End-Stage Liver Disease) criteria, or the APASL (Asian Pacific Association for the Study of the Liver) definition may determine which patients qualify for enrollment. Each system has specific thresholds for laboratory values and organ dysfunction that must be documented through standardized testing protocols. Researchers need this consistency to compare outcomes across different patients and study sites.^[1]

Laboratory testing for trial qualification typically follows strict schedules and uses standardized reference ranges. Blood samples may need to be drawn at specific time points, processed according to detailed protocols, and analyzed at central laboratories to ensure consistency. Tests commonly required include complete blood counts, comprehensive metabolic panels, liver function tests, coagulation studies, and inflammatory markers. Some trials also measure specialized substances in the blood that might indicate the severity of systemic inflammation, which plays a key role in the disease process.^[2]

Organ function assessment for trial enrollment must document the presence and severity of failures in specific organ systems. Kidney function is typically assessed using the most recent creatinine measurement and may require documentation of any dialysis or kidney replacement therapy. Brain function is evaluated through standardized scales that grade the severity of hepatic encephalopathy. Respiratory function requires documentation of oxygen needs, whether a patient requires mechanical ventilation, and specific measurements of blood oxygen levels.^[8]

Cardiovascular function assessment for research purposes often includes documentation of blood pressure readings, the need for medications to support blood pressure (called vasopressors), and measurements of heart rate. Some trials require echocardiograms—ultrasound examinations of the heart—to evaluate heart function more thoroughly. The presence of circulatory failure, defined by low blood pressure requiring medication support, significantly affects trial eligibility and risk stratification.^[15]

Clinical trials may exclude patients with certain diagnostic findings that could interfere with the study or indicate that the experimental treatment would be inappropriate. For example, trials might exclude individuals with uncontrolled infections, active cancer, advanced heart or lung disease independent of liver problems, or previous organ transplants. These exclusion criteria must be verified through appropriate diagnostic testing before a patient can enroll.^[4]

Imaging requirements for trial qualification vary depending on the study’s focus. Some trials require recent abdominal ultrasounds or CT scans to confirm the presence of cirrhosis, rule out liver tumors, or assess portal vein blood flow. Baseline imaging serves as a reference point for monitoring changes during the trial and helps ensure that participants have similar disease characteristics. The timing of these images relative to trial enrollment is often specified in the study protocol.^[4]

Infection screening represents a critical component of trial qualification diagnostics. Because bacterial infections commonly precipitate acute on chronic liver failure and influence outcomes, trials often require cultures of blood, urine, and abdominal fluid (if present) before enrollment. Some studies only accept patients with documented infections, while others specifically exclude those with certain types of infections. The results of these cultures help researchers understand whether the treatment being tested works differently in patients with and without active infections.^[3]

Documentation of the precipitating event—what triggered the acute on chronic liver failure episode—is often required for trial enrollment. This may involve additional diagnostic testing to identify and confirm factors like alcohol-related hepatitis, viral hepatitis reactivation, medication-related liver injury, or variceal bleeding. Trials may stratify patients based on these precipitating factors because they can affect both disease progression and response to treatment.^[1]

Serial measurements over time are common in clinical trials, with diagnostic tests repeated at predetermined intervals to track disease progression or improvement. This longitudinal testing provides the data needed to determine whether an experimental treatment is working. Patients enrolled in trials should expect more frequent blood draws and monitoring than they would receive in standard care, as these repeated measurements are essential for understanding treatment effects and safety.^[4]

Quality of life assessments, while not diagnostic tests in the traditional sense, are increasingly included in clinical trials for acute on chronic liver failure. These validated questionnaires measure how the disease affects daily functioning, mental health, and overall well-being. Though subjective, these assessments provide important information about the patient experience that laboratory values alone cannot capture. They help researchers understand whether new treatments improve not just organ function but also how patients feel and function in their daily lives.^[10]

Prognosis and Survival Rate

Prognosis

The outlook for people with acute on chronic liver failure depends heavily on the number and severity of organ failures, the ability to identify and treat precipitating events, and whether the patient is eligible for liver transplantation. The condition represents a critical turning point in chronic liver disease, with outcomes ranging from complete recovery to death within weeks. Several factors influence prognosis, including the patient’s age, the underlying cause of chronic liver disease, and how quickly medical intervention begins.

The severity grading system plays a crucial role in predicting outcomes. Patients are typically classified into three grades based on the number of failing organs. Those with grade 1 disease—characterized by single kidney failure or single non-kidney organ failure with kidney or brain problems—have better prospects for recovery compared to those with higher grades. Grade 2 involves two organ failures, while grade 3 indicates three or more failing organs, representing the most severe form of the condition.^[3]

The ability to reverse the precipitating event significantly affects prognosis. When the trigger can be identified and successfully treated—such as controlling an infection with antibiotics or stopping alcohol use in cases of alcohol-related hepatitis—the chances of recovery improve considerably. However, in many cases, doctors cannot identify a specific precipitating event, which can make treatment more challenging and outcomes less predictable.^[4]

Liver transplantation offers the best chance for long-term survival in appropriate candidates. Patients with acute on chronic liver failure who undergo successful liver transplantation have good post-transplant survival rates. However, only a limited number of patients are eligible for transplantation due to contraindications such as uncontrolled infections, severe heart or lung disease, active alcohol or drug use, or cancer. The shortage of available donor organs also means that some patients deteriorate while waiting for a transplant.^[10]

Survival rate

Short-term mortality rates for acute on chronic liver failure are notably high and increase with disease severity. Studies have shown that mortality rates vary significantly based on the grade of organ failure. Patients with grade 1 disease face approximately 22% risk of death within 28 days. This risk increases substantially for grade 2 patients, and those with grade 3 disease have mortality rates as high as 76% within the same timeframe.^[3]

The 28-day survival period is often used as a benchmark in research and clinical care because it represents a critical window during which most deaths occur. Patients who survive beyond this initial period may continue to improve, though they remain at risk for complications and recurrence. The early weeks after diagnosis represent the most dangerous time, when intensive medical management and close monitoring are essential.^[8]

Geographic location and the underlying cause of liver disease influence survival statistics. In Western countries, where alcohol-related cirrhosis is common and bacterial infections often trigger acute episodes, outcomes may differ from those in Asia-Pacific regions, where hepatitis B virus infection is the predominant cause and viral reactivation frequently precipitates acute on chronic liver failure. These regional differences reflect variations in available treatments, healthcare systems, and the nature of the underlying liver disease.^[4]

For patients who receive liver transplants, survival rates improve dramatically compared to those who do not receive transplants. While acute on chronic liver failure patients face severe risk of death while on the transplant waiting list, those who successfully undergo transplantation and survive the immediate post-operative period have good long-term outcomes. Post-transplant survival demonstrates that the condition is potentially reversible when the failing liver is replaced with a healthy one.^[10]

It is important to understand that survival statistics represent averages across many patients and cannot predict what will happen to any individual person. Some patients recover with supportive care alone, while others deteriorate rapidly despite aggressive treatment. The dynamic nature of acute on chronic liver failure means that a patient’s condition can change quickly, requiring ongoing reassessment and adjustment of treatment plans based on their response to therapy.^[2]

#1 Clinical Trials Search in Europe